François Raffi1, Abdel G Babiker2, Laura Richert3, Jean-Michel Molina4, Elizabeth C George2, Andrea Antinori5, Jose R Arribas6, Jesper Grarup7, Fleur Hudson2, Christine Schwimmer3, Juliette Saillard8, Cédrick Wallet3, Per O Jansson7, Clotilde Allavena9, Remko Van Leeuwen10, Jean-François Delfraissy11, Stefano Vella12, Geneviève Chêne3, Anton Pozniak13. 1. Infectious Diseases Department, University of Nantes, Nantes, France. Electronic address: francois.raffi@wanadoo.fr. 2. MRC Clinical Trials Unit at University College London, London, UK. 3. Inserm U897 Epidemiologie-Biostatistique, University of Bordeaux, Bordeaux, France. 4. Department of Infectious Diseases, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris and University of Paris Diderot, Paris, France. 5. Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy. 6. HIV Unit, Internal Medicine Service, Hospital La Paz, Madrid, Spain. 7. CHIP Department of Infectious Diseases and Rheumatology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 8. ANRS, Paris, France. 9. Infectious Diseases Department, University of Nantes, Nantes, France. 10. Academic Medical Centre, Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands. 11. Service de Médecine Interne - Immunologie Clinique, ANRS, CHU de Bicêtre, Paris France. 12. Istituto Superiore di Sanità, Rome, Italy. 13. Chelsea and Westminster NHS Foundation Trust, London, UK.
Abstract
BACKGROUND: Standard first-line antiretroviral therapy for HIV-1 infection includes two nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs), but these drugs have limitations. We assessed the 96 week efficacy and safety of an NtRTI-sparing regimen. METHODS: Between August, 2010, and September, 2011, we enrolled treatment-naive adults into this randomised, open-label, non-inferiority trial in treatment-naive adults in 15 European countries. The composite primary outcome was change to randomised treatment before week 32 because of insufficient virological response, no virological response by week 32, HIV-1 RNA concentration 50 copies per mL or higher at any time after week 32; death from any cause; any new or recurrent AIDS event; or any serious non-AIDS event. Patients were randomised in a 1:1 ratio to receive oral treatment with 400 mg raltegravir twice daily plus 800 mg darunavir and 100 mg ritonavir once daily (NtRTI-sparing regimen) or tenofovir-emtricitabine in a 245 mg and 200 mg fixed-dose combination once daily, plus 800 mg darunavir and 100 mg ritonavir once daily (standard regimen). This trial was registered with ClinicalTrials.gov, number NCT01066962. FINDINGS: Of 805 patients enrolled, 401 received the NtRTI-sparing regimen and 404 the standard regimen, with median follow-up of 123 weeks (IQR 112-133). Treatment failure was seen in 77 (19%) in the NtRTI-sparing group and 61 (15%) in the standard group. Kaplan-Meier estimated proportions of treatment failure by week 96 were 17·8% and 13·8%, respectively (difference 4·0%, 95% CI -0·8 to 8·8). The frequency of serious or treatment-modifying adverse events were similar (10·2 vs 8·3 per 100 person-years and 3·9 vs 4·2 per 100 person-years, respectively). INTERPRETATION: Our NtRTI-sparing regimen was non-inferior to standard treatment and represents a treatment option for patients with CD4 cell counts higher than 200 cells per μL. FUNDING: European Union Sixth Framework Programme, Inserm-ANRS, Gilead Sciences, Janssen Pharmaceuticals, Merck Laboratories.
BACKGROUND: Standard first-line antiretroviral therapy for HIV-1 infection includes two nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs), but these drugs have limitations. We assessed the 96 week efficacy and safety of an NtRTI-sparing regimen. METHODS: Between August, 2010, and September, 2011, we enrolled treatment-naive adults into this randomised, open-label, non-inferiority trial in treatment-naive adults in 15 European countries. The composite primary outcome was change to randomised treatment before week 32 because of insufficient virological response, no virological response by week 32, HIV-1 RNA concentration 50 copies per mL or higher at any time after week 32; death from any cause; any new or recurrent AIDS event; or any serious non-AIDS event. Patients were randomised in a 1:1 ratio to receive oral treatment with 400 mg raltegravir twice daily plus 800 mg darunavir and 100 mg ritonavir once daily (NtRTI-sparing regimen) or tenofovir-emtricitabine in a 245 mg and 200 mg fixed-dose combination once daily, plus 800 mg darunavir and 100 mg ritonavir once daily (standard regimen). This trial was registered with ClinicalTrials.gov, number NCT01066962. FINDINGS: Of 805 patients enrolled, 401 received the NtRTI-sparing regimen and 404 the standard regimen, with median follow-up of 123 weeks (IQR 112-133). Treatment failure was seen in 77 (19%) in the NtRTI-sparing group and 61 (15%) in the standard group. Kaplan-Meier estimated proportions of treatment failure by week 96 were 17·8% and 13·8%, respectively (difference 4·0%, 95% CI -0·8 to 8·8). The frequency of serious or treatment-modifying adverse events were similar (10·2 vs 8·3 per 100 person-years and 3·9 vs 4·2 per 100 person-years, respectively). INTERPRETATION: Our NtRTI-sparing regimen was non-inferior to standard treatment and represents a treatment option for patients with CD4 cell counts higher than 200 cells per μL. FUNDING: European Union Sixth Framework Programme, Inserm-ANRS, Gilead Sciences, Janssen Pharmaceuticals, Merck Laboratories.
Authors: Huldrych F Günthard; Michael S Saag; Constance A Benson; Carlos del Rio; Joseph J Eron; Joel E Gallant; Jennifer F Hoy; Michael J Mugavero; Paul E Sax; Melanie A Thompson; Rajesh T Gandhi; Raphael J Landovitz; Davey M Smith; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2016-07-12 Impact factor: 56.272
Authors: Gaetana Sterrantino; Mauro Zaccarelli; Antonio Di Biagio; Maria Luisa Biondi; Andrea Antinori; Giovanni Penco Journal: Infection Date: 2015-03-28 Impact factor: 3.553
Authors: Maile Y Karris; Sonia Jain; Tyler R C Day; Josué Pérez-Santiago; Miguel Goicoechea; Michael P Dubé; Xiaoying Sun; Celsa Spina; Eric S Daar; Richard H Haubrich; Sheldon Morris Journal: HIV Clin Trials Date: 2017-01-30
Authors: Charles R Swanepoel; Mohamed G Atta; Vivette D D'Agati; Michelle M Estrella; Agnes B Fogo; Saraladevi Naicker; Frank A Post; Nicola Wearne; Cheryl A Winkler; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christina M Wyatt Journal: Kidney Int Date: 2018-02-03 Impact factor: 10.612
Authors: Michael P Girouard; Paul E Sax; Robert A Parker; Babafemi Taiwo; Kenneth A Freedberg; Roy M Gulick; Milton C Weinstein; A David Paltiel; Rochelle P Walensky Journal: Clin Infect Dis Date: 2015-12-09 Impact factor: 9.079
Authors: Maile Y Karris; Sonia Jain; Vi Q Bowman; Gunter Rieg; Miguel Goicoechea; Michael P Dube; Shubha Kerkar; Carol Kemper; Catherine Diamond; Xiaoying Sun; Eric S Daar; Richard H Haubrich; Sheldon Morris Journal: J Acquir Immune Defic Syndr Date: 2016-06-01 Impact factor: 3.731